Sanofi SA ((SNY)), Sanofi ((DE:SNW)), Sanofi ((SNYNF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sanofi is conducting a study titled ‘Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus,’ aimed at evaluating the effectiveness and safety of Frexalimab (SAR441344) in patients with active Systemic Lupus Erythematosus (SLE). This Phase 2 study is significant as it explores a potential new treatment option for SLE, a chronic autoimmune disease.
The intervention being tested is Frexalimab, administered initially through an intravenous (IV) loading dose followed by subcutaneous (SC) injections over 24 weeks. The purpose of this treatment is to manage symptoms and improve the quality of life for SLE patients.
The study design is interventional, with participants randomly assigned to either the Frexalimab or placebo group. It employs a parallel intervention model with quadruple masking, ensuring that participants, care providers, investigators, and outcomes assessors are unaware of group assignments. The primary goal is treatment-focused.
The study began on November 10, 2021, and is currently recruiting participants. The primary completion date is yet to be determined, with the last update submitted on August 7, 2025. These dates are crucial as they indicate the study’s progress and timeline for potential results.
This update could positively influence Sanofi’s stock performance and investor sentiment, as successful results may lead to a new treatment option in the competitive autoimmune disease market. Investors should monitor this study’s progress for further developments.
The study is ongoing, with more details available on the ClinicalTrials portal.